keyword
MENU ▼
Read by QxMD icon Read
search

Colobreathe

keyword
https://www.readbyqxmd.com/read/24510624/colistimethate-sodium-dry-powder-for-inhalation-a-review-of-its-use-in-the-treatment-of-chronic-pseudomonas-aeruginosa-infection-in-patients-with-cystic-fibrosis
#1
REVIEW
Daniel Conole, Gillian M Keating
Historically, the polymyxin antibacterial colistin has been administered as intravenous or nebulized colistimethate sodium in patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa infection. More recently, colistimethate sodium has been formulated as a dry powder (Colobreathe(®)) to be administered via a hand-held Turbospin(®) inhaler. Compared with nebulized colistimethate sodium, the colistimethate sodium dry powder for inhalation (DPI) formulation reduces treatment time and improves patient convenience...
March 2014: Drugs
https://www.readbyqxmd.com/read/24290164/colistimethate-sodium-powder-and-tobramycin-powder-for-inhalation-for-the-treatment-of-chronic-pseudomonas-aeruginosa-lung-infection-in-cystic-fibrosis-systematic-review-and-economic-model
#2
REVIEW
P Tappenden, S Harnan, L Uttley, M Mildred, C Carroll, A Cantrell
BACKGROUND: Cystic fibrosis (CF) is an inherited condition characterised by the abnormal transport of chloride ions across transporting epithelia. This leads to the production of thick sticky mucus in the lungs, pancreas, liver, intestine and reproductive tract, and an increase in the salt content in sweat. Among other problems, people with CF experience recurrent respiratory infections and have difficulties digesting food. CF affects over 9000 individuals in the UK. CF shortens life expectancy and adversely affects quality of life...
December 2013: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/23135343/safety-efficacy-and-convenience-of-colistimethate-sodium-dry-powder-for-inhalation-colobreathe-dpi-in-patients-with-cystic-fibrosis-a-randomised-study
#3
RANDOMIZED CONTROLLED TRIAL
Antje Schuster, Cynthia Haliburn, Gerd Döring, Martin Harris Goldman
PURPOSE: To assess efficacy and safety of a new dry powder formulation of inhaled colistimethate sodium in patients with cystic fibrosis (CF) aged ≥6 years with chronic Pseudomonas aeruginosa lung infection. STUDY DESIGN AND METHODS: A prospective, centrally randomised, phase III, open-label study in patients with stable CF aged ≥6 years with chronic P aeruginosa lung infection. Patients were randomised to Colobreathe dry powder for inhalation (CDPI, one capsule containing colistimethate sodium 1 662 500 IU, twice daily) or three 28-day cycles with twice-daily 300 mg/5 ml tobramycin inhaler solution (TIS)...
April 2013: Thorax
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"